An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

This pilot, non-interventional, observational, Web-based, prospective cohort study is
designed to collect self-reported safety and effectiveness and genetic data from subjects
with locally recurrent breast cancer (BC) or metastatic breast cancer (MBC), metastatic
colorectal cancer (MCRC), metastatic non-squamous non-small cell lung cancer (MNSCLC),
recurrent glioblastoma (RGBM), or metastatic renal cell cancer (MRCC) in the United States
who have been previously treated with Avastin (bevacizumab). The cohort will be composed of
male and female subjects who have been diagnosed with locally recurrent BC or MBC, MCRC,
MNSCLC, RGBM, or MRCC who have received treatment with bevacizumab in combination with
chemotherapy, which started prior to or up to 31 December 2012. Participants will be
self-referred to this study. They will be recruited online via a number of sources,
including through the involvement of patient advocacy groups, social media tools,
traditional media, physicians, and events to raise awareness of this study. After
appropriate informed consent and authorization are obtained, data will be collected directly
from subjects in an online survey. Participants will be contacted electronically to complete
quarterly follow-up surveys. The follow-up period will be 1 year from responding to the
baseline survey. DNA collection will be performed as part of this study. DNA will be
extracted from saliva, which will be provided by the subject utilizing a collection kit sent
to the participants for at-home use.